- In April 2025, Assembly Biosciences presented promising data for ABI‑5366, a long‑acting HSV helicase‑primase inhibitor, at the ESCMID Global conference. Interim Phase 1a/1b results showed favorable safety, pharmacokinetics (with ~20-day half-life), and strong activity against both HSV‑1 and HSV‑2—supporting potential once‑weekly or monthly oral dosing
- In May 2025, Moderna’s mRNA‑1608 HSV‑2 vaccine candidate completed enrollment in its Phase 1/2 trial. This mRNA vaccine, targeting both HSV‑1 and HSV‑2, is designed to elicit robust neutralizing antibody and T-cell responses; the study is expected to deliver full data by April 2025
- In April 2025, OpenPR’s analysis of the herpes simplex drug pipeline noted innovative therapies such as PRITELIVIR (AIC‑316), mRNA‑1608, and BNT163, with PRITELIVIR expected to launch in the U.S. by 2026 and the U.K./Japan by 2027
